Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study

World Journal of Surgical Oncology

Chen Gang³  Li Zuyun³  Gopaul Roodrajeetsing²  Wen Xin³  Zhang Changwen³  Luo Feifei³  Wickramaarachchi Mihiranganee Madushi³  Zhong Tengfei³  Dang Yiwu³  Huang Suning¹  Chen Wenjie³  Ruan Yushan² 

[1] Department of Radiology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People’s Republic China;Department of Neurosurgery, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People’s Republic China;Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People’s Republic China

关键词: Clinical features;    Immunohistochemistry;    Glioma;    CDK5;   

Others  :  1221431
DOI  :  10.1186/s12957-015-0629-z

 received in 2015-02-13, accepted in 2015-06-16,  发布年份 2015

【 摘 要 】

Background

Previous studies suggested that expression of cyclin-dependent kinase 5 (CDK5) may promote the migration and invasion of human glioma cells. In this study, we aimed to evaluate the clinical value of CDK5 in different grades of glioma in relation to Ki-67 labeling index (LI).

Methods

We firstly assessed by immunohistochemistry the expression of CDK5 in 152 glioma tissues and 16 normal brain tissues and further explored the relationship between CDK5 expression and other clinical features.

Results

The positive ratio of CDK5 in gliomas (57.2 %) was higher than that in normal brain tissues (12.5 %, P = 0.001). Difference of CDK5 expression among four World Health Organization (WHO) grades was statistically significant (P = 0.001). The significant differences of CDK5 expression were also observed between WHO I glioma (34.8 %) and WHO III glioma (62.5 %), as well as WHO IV glioma (82.8 %; P = 0.026, P < 0.001, respectively). Furthermore, Spearman’s rank correlation confirmed that CDK5 was positively correlated with the pathological grade of glioma (r = 0.831, P < 0.001). The CDK5 expression was also positively correlated with Ki-67 LI (r = 0.347, P < 0.001).

Conclusions

The current result suggests that CDK5 may play an essential role in the tumorigenesis and aggressiveness of gliomas.

【 授权许可】

   
2015 Yushan et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al.. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
• [2]Huse JT, Aldape KD. The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clin Cancer Res. 2014; 20(22):5601-11.
• [3]Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S et al.. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol. 2009; 68(11):1219-28.
• [4]Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA et al.. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013; 2: Article ID e109
• [5]Choi H, Bang JI, Cheon GJ, Kim YH, Park CK, Park SH et al.. 18F-Fluorodeoxyglucose and 11C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas. Nucl Med Commun. 2014.
• [6]Li J, Taich ZJ, Goyal A, Gonda D, Akers J, Adhikari B et al.. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget. 2014; 5(17):7342-56.
• [7]Castro-Alvarez JF, Uribe-Arias SA, Mejia-Raigosa D, Cardona-Gomez GP. Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach. Front Aging Neurosci. 2014; 6:232.
• [8]Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K. CDK5 activator protein p25 preferentially binds and activates GSK3beta. 2014.
• [9]Odemuyiwa SO, Ilarraza R, Davoine F, Logan MR, Shayeganpour A, Wu Y et al.. Cyclin-dependent kinase 5 regulates degranulation in human eosinophils. Immunology. 2014.
• [10]Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD et al.. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012; 23(15):2856-66.
• [11]Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW et al.. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010; 70(11):4460-9.
• [12]Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V et al.. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013; 24(4):499-511.
• [13]Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu DX et al.. CDK5 is essential for TGF-beta1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep. 2013; 3:2932.
• [14]Miyamoto Y, Yamauchi J, Chan JR, Okada A, Tomooka Y, Hisanaga S et al.. Cdk5 regulates differentiation of oligodendrocyte precursor cells through the direct phosphorylation of paxillin. J Cell Sci. 2007; 120(Pt 24):4355-66.
• [15]Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci U S A. 2008; 105(21):7570-5.
• [16]Rai A, Tripathi S, Kushwaha R, Singh P, Srivastava P, Sanyal S et al.. CDK5-induced p-PPARgamma (Ser 112) downregulates GFAP via PPREs in developing rat brain: effect of metal mixture and troglitazone in astrocytes. Cell Death Disease. 2014; 5: Article ID e1033
• [17]Lagace DC, Benavides DR, Kansy JW, Mapelli M, Greengard P, Bibb JA et al.. Cdk5 is essential for adult hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2008; 105(47):18567-71.
• [18]Qu D, Xu H, Han X, Wang Y, Ouyang C. Expression of CyclinD1 and Ki-67 proteins in gliomas and its clinical significance. Eur Rev Med Pharmacol Sci. 2014; 18:516-9.
• [19]Huang S, Chen G. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. 2014;2014:605236. doi:10.1155/2014/605236.
• [20]Trabelsi S, Brahim DH, Ladib M, Mama N, Harrabi I, Tlili K et al.. Glioma epidemiology in the central Tunisian population: 1993–2012. Asian Pac J Cancer Prev. 2014; 15(20):8753-7.
• [21]Gomori E, Pal J, Kovacs B, Doczi T. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol. 2012; 7:8. BioMed Central Full Text
• [22]Xu S, Li X, Gong Z, Wang W, Li Y, Nair BC et al.. Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration. Mol Cell Proteomics. 2014; 13(11):2986-3000.
• [23]Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal. 2012; 24(1):44-52.
• [24]Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol (Northwood, London, England). 2011; 28(3):673-8.
• [25]Levacque Z, Rosales JL, Lee KY. Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients. Cell Cycle. 2012; 11(21):4093-5.
• [26]Sato Y, Taoka M, Sugiyama N, Kubo K, Fuchigami T, Asada A et al.. Regulation of the interaction of disabled-1 with CIN85 by phosphorylation with cyclin-dependent kinase 5. Genes Cells. 2007; 12(12):1315-27.
• [27]Ajay AK, Upadhyay AK, Singh S, Vijayakumar MV, Kumari R, Pandey V et al.. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol Cancer. 2010; 9:204. BioMed Central Full Text
• [28]Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA et al.. CDK5 is a major regulator of the tumor suppressor DLC1. J Cell Biol. 2014; 207(5):627-42.
• [29]Park AY, Shen TL, Chien S, Guan JL. Role of focal adhesion kinase Ser-732 phosphorylation in centrosome function during mitosis. J Biol Chem. 2009; 284(14):9418-25.
• [30]Tsai LH, Takahashi T, Caviness VS, Harlow E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Dev (Cambridge, England). 1993; 119(4):1029-40.
• [31]Gao C, Negash S, Wang HS, Ledee D, Guo H, Russell P et al.. Cdk5 mediates changes in morphology and promotes apoptosis of astrocytoma cells in response to heat shock. J Cell Sci. 2001; 114(Pt 6):1145-53.
• [32]Catania A, Urban S, Yan E, Hao C, Barron G, Allalunis-Turner J. Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells. Neuro-Oncology. 2001; 3(2):89-98.
• [33]Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH et al.. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem. 2011; 286(38):33141-9.